Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Kane Biotech Inc. V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. It has a portfolio of biotechnologies and products, which includes StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm. Its Wound Care & Surgical division is focused on the product development of DispersinB for applications in chronic wound care. Its bluestem product line includes water additives, chews, spray and dental wipes. Its other products in development stage include Coactiv+, antimicrobial wound rinse for use in acute and chronic wounds; Coactiv+, antimicrobial surgical hydrogel for use in surgical and acute wounds, and DispersinB Gel for prosthetic joint infection. It also provides Scalp Detoxifier, Shampoo and Shampoo Bars. Its primary markets for its technologies are animal health and human health.


TSXV:KNE - Post by User

Comment by francoisl13on May 01, 2023 10:18am
70 Views
Post# 35422671

RE:It's moving...

RE:It's moving...Boy oh boy, the FDA is taking sooooooooooooo long to approve Coactiv+....well, I guess that Dr. Schultz knew better than our ceo about the approval process....it will be Q2 (or later...). So, in short, commercialization will come later than expected (or promised) and it is clear that their message is not aligned - kind of surprising for such a small company.
It would be nice to get an update regarding the work being done to 'refurbish' the board of directors.
GLTA

<< Previous
Bullboard Posts
Next >>